麻豆视频

Global DTC DNA Test Kits Market Trends and Insights

Ancestry Testing Segment is Expected to Witness Growth Over the Forecast Period

An ancestry test is a DTC DNA-based test that reads specific locations of a subject's genome, to find or validate ancestral hereditary relationships or to evaluate the ethnic combination of an individual. The increasing number of people who are interested in knowing their ancestors and family trees is increasing the demand for DTC DNA test kits, especially in developing countries. The ancestry testing entails comparing the frequencies of many DNA variants found in an individual with those found in reference populations drawn from all over the world. In addition, ancestry testing is also performed to identify the carrier of any hereditary diseases or conditions such as polycystic kidney disease, breast cancer, Alzheimer's disease, various inborn errors of metabolism, and cystic fibrosis.

The increasing demand for ancestry testing across the globe is one of the major factors propelling the segment growth over the forecast period. For instance, as per the study published by the National Library of Medicine in March 2020, more than 26.0 million people have taken at-home ancestry tests across the globe in February 2020.

Therefore, considering the above mentioned factors, the ancestry testing segment is expected to witness significant growth over the forecast period.

North America is Expected to Dominate the DTC DNA Test Kits Market Over the Forecast Period

The growth of the market in North America is majorly due to the rising prevalence of congenital anomalies. For instance, as per the report published by the Centers for Disease Control and Prevention in 2021, one in every 33 babies in the United States are born with birth defects every year. In the North America region, the United States is expected to witness the largest market share owing to the factors such as easy acceptance of such kits in the country and high disposable income.

Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players in the United States are some of the factors driving the growth of the DTC DNA test kits market in the country. For instance, in August 2020, Ancestry launched AncestryHealth equipped with Next Generation Sequencing (NGS), which offers comprehensive data on common inherited health conditions. It is designed to help people to understand their risk of developing certain inheritable health conditions. Such continuous product launches are anticipated to drive the growth of the market in the country.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

Regulatory Landscape

Regulation of DTC DNA test kits continues to tighten across major markets, with the United States shifting oversight for many laboratory-developed tests (LDTs) toward a medical-device framework. In May 2024, the US FDA published a final rule (89 FR 37286) to phase out broad enforcement discretion for LDTs over four years, and May 2025 marked the start of the first stage of this phaseout, including requirements around Medical Device Reporting (MDR), corrections and removals, and complaint handling. This raises compliance expectations for lab-based genetic testing that can underpin DTC offerings, particularly around quality systems and post-market obligations.

In Europe, Regulation (EU) 2017/746 (IVDR) applies to in vitro diagnostic devices, including tests intended for lay users. It emphasizes performance evaluation and usability for home testing and increases the role of Notified Body involvement for many IVDs. At the same time, genetic privacy governance is expanding at the state level in the United States, increasing multi-jurisdictional compliance complexity for DTC genetic testing companies that collect and use genetic data. For example, South Dakota SB 49 becomes effective in July 2026, adding requirements around consent, disclosure, and consumer data rights for DTC genetic testing activities in that state.

Market Opportunities and Future Outlook

The market is creating whitespace for DTC providers that can pair consumer-friendly kits with stronger clinical governance and privacy-by-design operations as regulatory scrutiny rises on both test quality and data handling. The US FDA LDT final rule published on May 6, 2024 moves many lab-based tests toward medical device-style oversight, and it pushes companies to operationalize complaint handling, MDR readiness, and quality processes that can support broader distribution and partnerships. In parallel, rapid expansion of state genetic privacy laws (including Utah HB 182, Indiana HB 1521, Montana SB 163, and South Dakota SB 49 effective July 1, 2026) makes consent management, disclosure controls, and data-rights workflows a competitive differentiator for DTC genetic testing platforms operating nationally.

Demand-side evidence for genetic testing also continues to show up in payer and utilization signals, even when not purely DTC. A US HHS Office of Inspector General report noted that in 2024, genetic tests accounted for 43% of all Medicare Part B lab spending, totaling over USD 3.6 billion. Against this backdrop, DTC companies have room to expand beyond ancestry into health-related services that are better integrated with medical records, downstream care pathways, and clearer clinical validity communication, while still enabling consumer access through saliva and cheek swab collection. Moves toward whole-genome sequencing and richer longitudinal interpretations also increase the need for robust informed-consent practices, data security, and re-identification risk controls, creating specific opportunities for vendors that can combine lower sequencing costs with durable trust and compliance.